ViroMed’s CAR-T Therapy Attracts bluebird
This article was originally published in PharmAsia News
ViroMed has found a global partner to develop immune-oncology cell therapies. It and bluebird bio have reached an agreement worth up to $49m to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed’s proprietary humanized antibody.
Register for our free email digests: